Valuation: BioRestorative Therapies, Inc.

Market Cap 9.82M 8.6M 7.9M 7.36M 13.93M 937M 14.2M 95.05M 36.83M 459M 36.89M 36.08M 1.58B P/E 2026 *
-0.81x
P/E 2027 * -0.99x
Enterprise Value 9.82M 8.6M 7.9M 7.36M 13.93M 937M 14.2M 95.05M 36.83M 459M 36.89M 36.08M 1.58B EV / Sales 2026 *
6.99x
EV / Sales 2027 * 4.25x
Free-Float
87.87%
Yield 2026 *
-
Yield 2027 * -
1 day+3.73%
1 week+0.70%
Current month+6.38%
1 month-1.57%
3 months+40.35%
6 months-65.96%
Current year-65.96%
1 week 0.35
Extreme 0.3512
0.41
1 month 0.32
Extreme 0.32
0.43
Current year 0.16
Extreme 0.1593
1.28
1 year 0.16
Extreme 0.1593
1.89
3 years 0.16
Extreme 0.1593
4.6
5 years 0.16
Extreme 0.1593
32
10 years 0.16
Extreme 0.1593
20,040
Manager TitleAgeSince
Chief Executive Officer 55 2020-11-15
Director of Finance/CFO 59 2021-11-03
Investor Relations Contact - -
Director TitleAgeSince
Chairman 55 2020-11-15
Director/Board Member 60 2021-10-28
Director/Board Member 28 2026-06-11
Date Insider Type Main position Quantity % Market Cap.
25-10-05Free

Chief Technology Officer

23,438 0.2938%
25-10-05Free

Chief Executive Officer

27,344 0.3427%
25-02-13Other

Director

52,632 0.7606%
Change 5-day change 1-year change 3-year change Capi.($)
+3.73%+0.70%-75.46%-90.93% 9.82M
+3.98%+10.23%+73.54%+132.19% 56.21B
-3.12%+5.11%+71.57%+94.67% 55.38B
+3.86%+8.13%-9.27%-9.62% 23.75B
+4.30%+7.87%+14.32%+428.91% 23.19B
+3.64%+10.54%+39.81%-4.50% 18.14B
+4.11%+9.85%+42.56%-27.36% 16.84B
+2.57%+20.26%+181.98%+355.99% 15.86B
+3.50%+5.64%+28.04%+192.26% 13.56B
+7.20%+10.70%+42.91% - 12.97B
Average +3.00%+6.23%+41.00%+119.07% 23.59B
Weighted average by Cap. +1.99%+6.09%+57.10%+135.02%

Financials

2026 *2027 *
Net sales 1.4M 1.23M 1.13M 1.05M 1.99M 134M 2.03M 13.59M 5.27M 65.65M 5.28M 5.16M 227M 2.31M 2.02M 1.86M 1.73M 3.28M 221M 3.34M 22.37M 8.67M 108M 8.68M 8.49M 373M
Net income -13.52M -11.83M -10.87M -10.13M -19.18M -1.29B -19.55M -131M -50.7M -632M -50.78M -49.67M -2.18B -15.56M -13.61M -12.51M -11.66M -22.07M -1.48B -22.49M -151M -58.33M -727M -58.42M -57.14M -2.51B
Net Debt - -
Logo BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Employees
14
Date Price Change Volume
26-07-02 US$0.3999 +3.71% 270,322
26-07-01 US$0.3856 +2.55% 286,084
26-06-30 US$0.3760 +1.62% 635,108
26-06-29 US$0.3700 +0.11% 259,226
26-06-26 US$0.3696 -6.19% 293,900
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.3999USD
Average target price
8.000USD
Spread / Average Target
+1,900.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BRTX Stock